Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb against the myostatin protein (GDF8; MSTN)
Molecular Target Myostatin (MSTN) (GDF8)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD); Treat limb girdle muscular dystrophy 2I (LGMD2I); Treat muscular dystrophy
Regulatory Designation U.S. - Fast Track (Treat Duchenne muscular dystrophy (DMD));
U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD));
EU - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today